Glue Embolism: a Rare Cause of Pulmonary Embolism Pervez Ashraf, Syed Afzal-Ul-Haq Haqqi, Hafeezullah Shaikh and Asif J

Total Page:16

File Type:pdf, Size:1020Kb

Glue Embolism: a Rare Cause of Pulmonary Embolism Pervez Ashraf, Syed Afzal-Ul-Haq Haqqi, Hafeezullah Shaikh and Asif J CASE REPORT Glue Embolism: A Rare Cause of Pulmonary Embolism Pervez Ashraf, Syed Afzal-ul-Haq Haqqi, Hafeezullah Shaikh and Asif J. Wakani ABSTRACT N-butyl-2-cyanoacrylate is widely used to sclerose bleeding gastric varices. We report the case of a 65-year-old lady, known case of cirrhosis secondary to hepatitis C infection, who presented to the emergency department with coffee ground vomiting and melena for four days. Gastroscopy showed non-bleeding small esophageal varices, mild portal hypertensive gastropathy and a large gastric fundal varix. Injection sclerotherapy was completed successfully and haemostasis was secured. During the procedure, she was hemodynamically stable with an oxygen saturation of 98%. Immediately after the procedure, she went into cardiopulmonary arrest; cardiopulmonary resuscitation (CPR) was started, but she could not be revived. A provisional diagnosis of pulmonary embolism was made. X-ray chest showed linear hyperdense shadows in both pulmonary arteries and in some of their branches, which were not seen on pre-procedural chest X-ray. The patient died of massive pulmonary embolism as confirmed on X-ray chest. Key words: Glue embolism. Pulmonary embolism. Varices. Hepatitis C. Cyanoacrylate embolism. Chest X-ray. INTRODUCTION stable vital signs with normal respiratory and Upper gastrointestinal haemorrhage (UGIH) secondary cardiovascular systems. Physical examination revealed to fundal (gastric) variceal bleeding is an uncommon normal lung examination, abdominal ascites with and life-threatening complication of portal hypertension. umbilical hernia and mild splenomegaly. Gastric varices bleed less frequently than esophageal Laboratory testing revealed haemoglobin level of varices, but bleeding from gastric fundal varices (GV) 7.5 g/dl; leukocytes count of 5.5 x 109/l; platelets count tends to be more severe and is associated with a high of 71 x 109/l; prothrombin time of 17/9 seconds; and mortality rate. serum creatinine level of 1.2 mg/dl. Chest X-ray did not Endoscopic variceal ligation of esophageal varices is reveal any abnormality. recognized as a main stay of treatment modality now a On admission to the gastroenterology ward, the patient days. Endoscopic treatments with tissue glue cyano- was given intravenous (I/V) ceftriaxone, I/V sandostatin acrylate (N-butyl-2-cyanoacrylate) has been used infusion and packed red blood cells. Upper GI successfully in many countries for 20 years and is endoscopy showed non-bleeding small esophageal considered by many clinicians to be the optimal initial varices, mild portal hypertensive gastropathy and a treatment for bleeding gastric varices. Many physicians large gastric varix in the fundus (Figure 1). may be unaware of glue embolization because of its Endoscopic sclerotherapy was performed with a solution rarity. Important risk factors for first gastric variceal bleeding are child pugh class B and C, red wale marks, containing 4 ml of N-butyl cyanoacrylate and 8 ml multiple and large size of the varices located in the lipoidol (a lipid based radiological contrast agent to fundus.2 prevent premature polymerization of the glue). A 19-guage needle with 10 ml syringe was used to inject We report a case of pulmonary embolization of N-butyl- the large gastric varix. Injection sclerotherapy was 2-cyanoacrylate that occurred after endoscopic injection completed successfully and haemostasis confirmed. therapy for gastric variceal bleeding. During the procedure, she was hemodynamically stable with an oxygen saturation of 98%. CASE REPORT Immediately after the procedure, her oxygen saturation This 65-year-old lady, who was a cirrhotic secondary to dropped and she became tachycardic. She was given hepatitis C infection (child turcotte pugh class C) supplemental oxygen therapy and was shifted to presented to the emergency department with a 4 days monitored setting. A chest X-ray was ordered, she went history of coffee coloured vomiting and melena. She had into cardiopulmonary arrest, CPR was started, but she could not be revived. A provisional diagnosis of Department of Gastroenterology, Liaquat National Hospital, pulmonary embolism was made. X-ray chest showed Karachi. linear hyperdense shadows in both pulmonary arteries Correspondence: Dr. Hafeezullah Shaikh, Bunglow No. G-72, and in some of their branches (Figure 2), which were not Defence View, Phase II, Expressway Road, Karachi. seen on pre-procedural chest X-ray. This confirmed the E-mail: [email protected] diagnosis of massive pulmonary embolism as the cause Received September 06, 2010; accepted July 27, 2011; of death. 574 Journal of the College of Physicians and Surgeons Pakistan 2011, Vol. 21 (9): 574-576 Glue embolism Other less common, but potentially serious compli- cations include abscesses and bacteremia. Rupture of esophagogastric varices is one of the most severe complications of portal hypertension in patients with liver cirrhosis. Multidisciplinary approach and close coordi- nation among gastroenterologists, surgical team and interventional radiologists will be required for the proper management of FVO. Obturation of bleeding fundal varices is technically difficult and demanding because of its location and size.8 Sohendra et al. first described in 1986 that hemostasis of bleeding gastric varices could be achieved by injecting the tissue adhesive agent with butyl cyanoacrylate.9 Figure 1: Endoscopic image showing large gastric fundal varix. Various other treatment modalities are transjugular intrahepatic portosystemic shunts (TIPS), balloon occluded retrograde transvenous obliteration techni- ques (BORTO) and gastric variceal ligation, although this modality is falling out of favour. Intra-gastric balloon tamponade is used as a bridge to further therapy. Liver transplantation is the final option. N-butyl-2-cyanoacrylate (NBC) is the only promising agent. In Pakistan, the rate for primary haemostasis with cyanoacrylate injection is consistent with the reported rate of 90% to 97% even as in other countries.10 Pulmonary embolism is a rare and potentially serious complication, but systemic (arterial) embolization has also been reported. An important cause of increased risk of embolism during procedure is instillation of more than 1 ml of the histoacryl/lipiodol mixture per injection. Cyanoacrylate, when used to obliterate esophageal and Figure 2: Chest X-ray showing linear hyperdense shadows in both pulmonary arteries and in some of their branches. gastric varices, has been reported in the endoscopy and radiology literature to cause pulmonary emboli. Most DISCUSSION fundal gastric varices are supplied by short gastric and epiploic veins and drain to the left renal vein through a Fundal (gastric) varix obliterative therapy with N-butyl-2- large gastrorenal shunt. Cyanoacrylate is the treatment of choice for the management of acute gastric variceal bleeding and its Pulmonary glue embolism is difficult to diagnose and relation with decompensated liver cirrhosis was first manage. So because of diagnostic dilemma gastro- published in German literature in 1913.3,4 The incidence enterologists should have a high index of suspicion for of UGIH secondary to fundal (gastric) varices is embolism in the setting of tachycardia, chest pain, or relatively low, varies from 10% to 36% despite the fact of hypoxia after an endoscopic FVO therapy. its high prevalence rate in patients with decompensated liver cirrhosis ranging from 18% to 70%.5 Procedure- REFERENCES related complications of fundal varix obturation (FVO) 1. Sato T, Yamazaki K. Evaluation of therapeutic effects and are fever, recurrent bleeding, chest pain and ulceration. serious complications following endoscopic obliterative therapy Although, more life-threatening complications are with histoacryl. Clin Exp Gastroenterol 2010; 3:91-5. Epub 2010 embolization to the cerebral arteries, portal vein, lung, Jul 14. and splenic arteries have also been reported.6 Systemic 2. Kang EJ, Jeong WS, Jang YJ, Cho YJ, Lee HS, Kim GH, et al. embolization most likely occurs via the gastrorenal and Long-term result of endoscopic Histoacryl® (N-butyl-2- splenorenal veins, as it was also observed in this cyanoacrylate) injection for treatment of gastric varices. patient. Atrial septal defect is also another potential World J Gastroenterol 2011; 17:1494-500. route for paradoxical glue embolization. Splenic 3. Chen JZ, Freeman LM. Management of upper gastrointestinal infarction is compromised by exposure to histoacryl bleeding emergencies: evidence-based medicine and practical 7 (NBC) because of splenic vasculature involvement. considerations. World J Emerg Med 2011; 2:5-11. Journal of the College of Physicians and Surgeons Pakistan 2011, Vol. 21 (9): 574-576 575 Pervez Ashraf, Syed Afzal-ul-Haq Haqqi, Hafeezullah Shaikh and Asif J. Wakani 4. Sarin KS, Satapathy KS. Endoscopic management of esophageal 8. Hameed K, Khan Y, Saeed A, Ahmad I, Javed M, Rehman S, and gastric varices. Bombay Hosp J 2011; 53:342-4. et al. Injection sclerotherapy of bleeding gastric varices using 5. Sarin SK, Kumar A. Gastric varices: profile, classification,and manage- absolute alcohol. J Postgrad Med Inst 2010; 24:111-4. ment. Am J Gastroenterol 1989; 84:1244-9. 9. Soehendra N, Nam VC, Grimm H, Kempeneers I. Endoscopic obliteration of large esophagogastric varices with bucrylate. 6. Tan YM, Goh KL, Kamarulzaman A, Tan PS, Ranjeev P, Salem O, et al. Multiple systemic embolisms with septicemia after gastric variceal Endoscopy 1986; 18:25-6. obliteration with cyanoacrylate. Gastrointest Endosc 2002; 55:276-8. 10. Mumtaz K, Majid S, Shah H, Hameed K, Ahmed A, Hamid S, 7. Kurt M, Onal IK, Ibis M, Tas A, Ozderin YO, Okten RS. Splenic et al. Prevalence of gastric varices and results of sclerotherapy infarction: rare complication of N-butyl-2-cyanoacrylate injection with N-butyl 2 cyanoacrylate for controlling acute gastric variceal for gastric varices. Dig Endosc 2010; 22:74-75. bleeding. World J Gastroenterol 2007; 13:1247-51. lllllOlllll 576 Journal of the College of Physicians and Surgeons Pakistan 2011, Vol. 21 (9): 574-576 .
Recommended publications
  • Dispensing Solutions for Cyanoacrylate Adhesives White
    Dispensing Solutions for Cyanoacrylate Adhesives Contents How Cyanoacrylates Work .......................................................................3 Advantages of CAs ...................................................................................4 CA Dispensing Challenges .......................................................................4 Best Practices for Dispensing CAs .....................................................5-12 Best Systems for Dispensing CAs ....................................................13-14 Useful Resources ...................................................................................15 Introduction Cyanoacrylate adhesives, also known as CAs or cyanos, are highly effective at bonding many types of materials together in assembly processes. Often referred to as super glues, they exhibit high bond strength and fast cure times that help manufacturers speed production processes for higher throughput yields. This makes them an ideal choice for assembling products in a variety of industries, including automotive, electronics, life sciences, defense, and consumer goods. Though beneficial, these moisture-cure adhesives can be a challenge, especially when your assembly process requires precise, repeatable dispensing. This paper outlines proper handling methods and dispensing solutions for successful CA dispensing. Find out how to minimize material waste by more than 60% while also minimizing operator exposure to the adhesive. Speed your production processes while producing higher quality parts with
    [Show full text]
  • N-Butyl Cyanoacrylate Synthesis. a New Quality Step Using Microwaves
    Molecules 2014, 19, 6220-6227; doi:10.3390/molecules19056220 OPEN ACCESS molecules ISSN 1420-3049 www.mdpi.com/journal/molecules Article n-Butyl Cyanoacrylate Synthesis. A New Quality Step Using Microwaves Yaquelin Ramos Carriles 1,*, Rubén Álvarez Brito 1, Ricardo Martínez Sánchez 2, Elayma Sánchez Acevedo 1, Paola Rodríguez Domínguez 1 and Wolf-Dieter Mueller 3 1 Chemistry-Physics Department, Faculty of Chemistry, University of Havana, Zapata and G, Vedado, Havana 10400, Cuba; E-Mails: [email protected] (R.Á.B.); [email protected] (E.S.A.); [email protected] (P.R.D.) 2 Polymers Laboratory, IMRE, University of Havana, Zapata and G, Vedado, Havana 10400, Cuba; E-Mail: [email protected] 3 Charité-Universitaetsmedizin Berlin, Assmannshauser Str.4-6, Berlin 14197, Germany; E-Mail: [email protected] * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +537-878-0684; Fax: +537-837-5774. Received: 4 April 2014; in revised form: 5 May 2014 / Accepted: 13 May 2014 / Published: 15 May 2014 Abstract: Alkyl cyanoacrylates are interesting products for use in industry because of their properties enabling them to stick together a wide range of substrates. n-Butyl cyanoacrylate is one of the most successfully used tissue adhesives in the field of medicine because it exhibits bacteriostatic and haemostatic characteristics, in addition to its adhesive properties. At present, its synthesis is performed with good yields via Knoevenagel condensation using conventional sources of heating, but this requires a long processing time. The aim of this work was to look for a new way of synthesising n-butyl cyanoacrylate using microwave irradiation as the source of heating.
    [Show full text]
  • Gluture Topical Tissue Adhesive Other Means of Identification Synonyms Gluture® * Topical Vet Adhesive Recommended Use Veterinary Adhesive
    SAFETY DATA SHEET 1. Identification Product identifier GLUture Topical Tissue Adhesive Other means of identification Synonyms GLUture® * Topical Vet Adhesive Recommended use Veterinary Adhesive. Recommended restrictions Not for human use Manufacturer/Importer/Supplier/Distributor information Company Name (US) Zoetis Inc. 10 Sylvan Way Parsippany, New Jersey 07054 (USA) Rocky Mountain Poison 1-866-531-8896 and Drug Center Product Support/Technical 1-800-366-5288 Services Emergency telephone CHEMTREC (24 hours): 1-800-424-9300 numbers International CHEMTREC (24 hours): +1-703-527-3887 Company Name (EU) Zoetis Belgium S.A. Mercuriusstraat 20 1930 Zaventem Belgium Emergency telephone International CHEMTREC (24 hours): +1-703-527-3887 number Contact E-Mail [email protected] 2. Hazard(s) identification Physical hazards Flammable liquids Category 4 Health hazards Skin corrosion/irritation Category 2 Serious eye damage/eye irritation Category 2A Sensitization, skin Category 1 Environmental hazards Not classified. OSHA defined hazards Not classified. Label elements Signal word Warning Hazard statement Combustible liquid. Causes skin irritation. May cause an allergic skin reaction. Causes serious eye irritation. Precautionary statement Prevention Keep away from flames and hot surfaces-No smoking. Avoid breathing mist or vapor. Wash thoroughly after handling. Contaminated work clothing must not be allowed out of the workplace. Wear protective gloves/eye protection/face protection. Response If on skin: Wash with plenty of water. If skin irritation or rash occurs: Get medical advice/attention. If in eyes: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. If eye irritation persists: Get medical advice/attention. Take off contaminated clothing and wash before reuse.
    [Show full text]
  • Safety, Efficacy, and Outcomes of N-Butyl Cyanoacrylate Glue Injection Through the Endoscopic Or Radiologic Route for Variceal G
    Journal of Clinical Medicine Review Safety, Efficacy, and Outcomes of N-Butyl Cyanoacrylate Glue Injection through the Endoscopic or Radiologic Route for Variceal Gastrointestinal Bleeding: A Systematic Review and Meta-Analysis Olivier Chevallier 1 ,Kévin Guillen 1 , Pierre-Olivier Comby 2, Thomas Mouillot 3 , Nicolas Falvo 1, Marc Bardou 3, Marco Midulla 1, Ludwig-Serge Aho-Glélé 4 and Romaric Loffroy 1,* 1 Department of Vascular and Interventional Radiology, Image-Guided Therapy Center, ImViA Laboratory-EA 7535, François-Mitterrand University Hospital, 14 Rue Paul Gaffarel, BP 77908, 21079 Dijon, France; [email protected] (O.C.); [email protected] (K.G.); [email protected] (N.F.); [email protected] (M.M.) 2 Department of Neuroradiology and Emergency Radiology, François-Mitterrand University Hospital, 14 Rue Paul Gaffarel, BP 77908, 21079 Dijon, France; [email protected] 3 Department of Gastroenterology and Hepatology, François-Mitterrand University Hospital, 14 Rue Paul Gaffarel, BP 77908, 21079 Dijon, France; [email protected] (T.M.); [email protected] (M.B.) 4 Department of Biostatistics and Epidemiology, François-Mitterrand University Hospital, 14 Rue Paul, Citation: Chevallier, O.; Guillen, K.; Gaffarel, BP 77908, 21079 Dijon, France; [email protected] Comby, P.-O.; Mouillot, T.; Falvo, N.; * Correspondence: [email protected]; Tel.: +33-380-293-358 Bardou, M.; Midulla, M.; Aho-Glélé, L.-S.; Loffroy, R. Safety, Efficacy, and Abstract: We performed a systematic review and meta-analysis of published studies to assess the Outcomes of N-Butyl Cyanoacrylate efficacy, safety, and outcomes of N-butyl cyanoacrylate (NBCA) injection for the treatment of variceal Glue Injection through the gastrointestinal bleeding (GIB).
    [Show full text]
  • Hummel Polymer Library
    Hummel Polymer Library Index Number Compound Name Index Number Compound Name 1 Pinewood pyrolyzate 27 Pine resin, fresh 2 Urea-formaldehyde resin 28 Poly(1,4-butylene pyrolyzate terephthalate) 3 Pinewood pyrolyzate 29 Polyester, terephthalic 4 Poly(acrylonitrile) acid 5 Poly(acrylonitrile:butadien 30 Polyester, terephthalic e:styrene) acid 6 Poly(fumaronitrile:styrene) 31 Poly(acrylonitrile:vinyliden 7 Polyamide-6 e chloride),3:1 8 Poly(ester urethane), MBI 32 Poly(1,4-butylene 9 Poly(ester urethane), MBI terephthalate) 10 Alkyd, sunflower oil acids, 33 Poly(acrylonitrile:methyl PAnh,MAnh,pentaerythrito methacrylate) l 34 Epoxy resin, Bisphenol A 11 Phenol resol + epichlorohydrin 12 Poly(isobutene) + ester 35 Methacrylate oligomer 13 Phenol resol, cured 36 Carboxymethylcellulose, 14 Poly(2,6-dimethyl-1,4- Na salt phenylene 37 Poly(vinylidene fluoride) ether)+polystyrene 38 Poly(vinyl chloride) 15 Polyester, tere- & 39 Alkyd, 26% linseed oil + isophthalic acids PAnh 16 Polyester, tere- & 40 Alkyd, 49% linseed oil + isophthalic acids PAnh 17 Polyester, tere- & 41 Alkyd, 26% linseed isophthalic acids oil+PAnh + melamine 18 Polyester, terephthalic resin acid 42 Alkyd, 49% linseed 19 Polyester, terephthalic oil+PAnh + melamine acid resin 20 Polyester, tere- & 43 Alkyd, 40% castor oil + isophthalic acids PAnh 21 Polyurethane, linear, 44 Alkyd, 68% castor oil + aliphatic PAnh 22 Polyester, tere- & 45 Alkyd, 68%castor isophthalic acids oil+PAnh + melamine 23 Polyester, tere- & resin isophthalic acids 46 Epoxy resin, Bisphenol A 24 Polyester, tere- & + epichlorohydrin isophthalic acids 47 Epoxy + melamine resins 25 Polyester, tere- & 1:1 isophthalic acids 48 Poly(vinyl butyral) 26 Polyester, tere- & 49 Epoxy resin + poly(vinyl isophthalic acids butyral) Hummel Polymer Library, page 1 of 29 Index Number Compound Name Index Number Compound Name 50 Melamine resin, etherified methacrylate:acrylonitrile) 51 Alkyd, aliphatic 92 Poly(methyl 52 Melamine-formaldehyde methacrylate:acrylonitrile) cond.
    [Show full text]
  • New Type Cyanoacrylate Medical Adhesive And
    (19) *EP003335738B1* (11) EP 3 335 738 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61L 24/06 (2006.01) A61L 24/04 (2006.01) (2006.01) (2006.01) 06.11.2019 Bulletin 2019/45 A61L 15/24 C09J 133/14 A61L 24/00 (2006.01) (21) Application number: 15900803.6 (86) International application number: (22) Date of filing: 19.08.2015 PCT/CN2015/087551 (87) International publication number: WO 2017/024606 (16.02.2017 Gazette 2017/07) (54) NEW TYPE CYANOACRYLATE MEDICAL ADHESIVE AND PREPARATION METHOD AND USE THEREOF NEUARTIGER MEDIZINISCHER CYANACRYLATKLEBSTOFF UND HERSTELLUNGSVERFAHREN UND VERWENDUNG DAVON ADHÉSIF MÉDICAL DE CYANOACRYLATE DE NOUVEAU TYPE, ET PROCÉDÉ DE PRÉPARATION ET UTILISATION DE CE DERNIER (84) Designated Contracting States: • YU, Shufang AL AT BE BG CH CY CZ DE DK EE ES FI FR GB Beijing 100176 (CN) GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO • WANG, Pengfei PL PT RO RS SE SI SK SM TR Beijing 100176 (CN) • SHAO, Jie (30) Priority: 11.08.2015 CN 201510489872 Beijing 100176 (CN) (43) Date of publication of application: (74) Representative: LLR 20.06.2018 Bulletin 2018/25 11, boulevard de Sébastopol 75001 Paris (FR) (73) Proprietor: Shen, Wei Beijing 100176 (CN) (56) References cited: WO-A1-02/09785 WO-A1-2015/059644 (72) Inventors: CN-A- 101 495 377 CN-A- 103 083 718 • SHEN, Wei CN-A- 104 710 953 US-A1- 2002 037 310 Beijing 100176 (CN) US-A1- 2002 037 310 US-A1- 2003 082 116 • XU, Jinghai Beijing 100176 (CN) Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations.
    [Show full text]
  • Patch Testing, 3Rd Edition: Update 2008 – 2015
    Patch testing, 3rd Edition: Update 2008 – 2015 Anton C. de Groot, MD, PhD Schipslootweg 5 8351 HV Wapserveen The Netherlands tel. +31(0)521320332 www.patchtesting.info [email protected] [email protected] This is an addendum to and an update of Patch Testing, 3 rd Edition (ISBN 978-90-813233-1-4). It contains informa- tion on new allergens , mostly chemicals described as contact allergens after publication of the book. The data presented here have mostly been published in Contact Dermatitis and Dermatitis (the two journals largely devoted to the subject of contact dermatitis) from March, 2008 through June, 2015. Also, updated information on a number of contact allergens already mentioned in Patch Testing is provided, notably new test concentrations and/or vehicles, modifications of advice previously given or other data such as newly reported photosensitivity or contact urticarial reactions. For the updated allergens, only the new information is given; it is recommended to assess the data in conjunction with the corresponding entries in Table 1 of Patch Testing , 3 rd Edition. Table 1 below provides an alphabetical listing of 275 individual chemicals or compounds and 66 synonyms for new and updated allergens. Of the 275 chemicals, 175 refer to NEW allergens, not included in the 2008 3 rd Edition of Patch Testing . There are 94 updates of test concentrations and 14 reports of immediate contact reactions (contact urticaria). For the new contact allergens, CAS numbers have now been provided. Table 1 has 6 vertical columns, which contain the following information: 1: Name of the chemical 2: Synonyms/other names 3: Patch test concentrations & vehicles, and reference numbers 4: Merck Index number 5: Monographs in the Ingredient Database of the Personal Care Council 6: Comments Column 1: Name of the chemical This column lists all chemicals, both ‘preferred names’ and ‘synonyms/other names’ alphabetically.
    [Show full text]
  • SAFETY DATA SHEETS This SDS Packet Was Issued with Item
    SAFETY DATA SHEETS This SDS packet was issued with item: 078679063 N/A SAFETY DATA SHEET ~etis 1. Identification Product identifier GLUture Topical Tissue Adhesive Other means of identification Synonyms GLUture® * Topical Vet Adhesive Recommended use Veterinary Adhesive. Recommended restrictions Not for human use Manufacturer/Importer/Supplier/Distributor information Company Name (US) Zoetis Inc. 10 Sylvan Way Parsippany, New Jersey 07054 (USA) Rocky Mountain Poison 1-866-531-8896 and Drug Center Product Support/Technical 1-800-366-5288 Services Emergency telephone CHEMTREC (24 hours): 1-800-424-9300 numbers International CHEMTREC (24 hours): +1-703-527-3887 Company Name (EU) Zoetis Belgium S.A. Mercuriusstraat 20 1930 Zaventem Belgium Emergency telephone International CHEMTREC (24 hours): +1-703-527-3887 number Contact E-Mail [email protected] 2. Hazard(s) identification Physical hazards Flammable liquids Category 4 Health hazards Skin corrosion/irritation Category 2 Serious eye damage/eye irritation Category 2A Sensitization, skin Category 1 Environmental hazards Not classified. OSHA defined hazards Not classified. Label elements Signal word Warning Hazard statement Combustible liquid. Causes skin irritation. May cause an allergic skin reaction. Causes serious eye irritation. Precautionary statement Prevention Keep away from flames and hot surfaces-No smoking. Avoid breathing mist or vapor. Wash thoroughly after handling. Contaminated work clothing must not be allowed out of the workplace. Wear protective gloves/eye protection/face protection. Response If on skin: Wash with plenty of water. If skin irritation or rash occurs: Get medical advice/attention. If in eyes: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do.
    [Show full text]
  • WO 2013/067510 Al 10 May 2013 (10.05.2013) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2013/067510 Al 10 May 2013 (10.05.2013) P O P C T (51) International Patent Classification: DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, A61B 19/00 (2006.01) HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, (21) International Application Number: ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, PCT/US2012/063572 NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, (22) International Filing Date: RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, 5 November 20 12 (05 .11.20 12) TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of regional protection available): ARIPO (BW, GH, (30) Priority Data: GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, 61/556,169 4 November 20 11 (04. 11.201 1) US UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, (71) Applicant: OP- MARKS, INC. [US/US]; 190 Ben Burton EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, Rd., Ste. G., Bogart, GA 30622 (US).
    [Show full text]
  • Cyanoacrylates for Skin Closure William H
    Dermatol Clin 23 (2005) 193 – 198 Cyanoacrylates for Skin Closure William H. Eaglstein, MD*, Tory Sullivan, MD Department of Dermatology and Cutaneous Surgery, University of Miami School of Medicine, 1600 NW 10th Avenue, RMSB 2023A, Miami, FL 33136, USA Cyanoacrylates (CAs), first produced in 1949 Butyl cyanoacrylate [1], are liquids that polymerize in the presence of moisture to form adhesives, glues, and films. The BCA is an intermediate-length CA that was the surgical use of these compounds was first proposed first CA to be widely used for cutaneous wound by Coover et al [2] in 1959. The short-chain cyano- closure. It has been available and widely used in acrylates (methyl, ethyl) [3,4] proved to be extremely Europe and Canada as Histoacryl Blue and Glustitch toxic to tissue, however, preventing their widespread since as early as the 1970s. Although the short-chain use as tissue glues. The short-chain CAs are used in CAs (methyl, ethyl) were toxic to tissue, BCA is nonmedical products, such as Krazy glue (Elmer’s, generally considered to be nontoxic when applied Columbus, Ohio), and although they are not intended topically. When used in an experimental model of for medical use, dermatologists have been quoted in incisional wound healing in hamsters, BCA resulted the popular press as recommending these glues for in less inflammation than 4.0 silk sutures on the treatment of fissures on fingers and toes [5]. Butyl histologic assessment [7]. Furthermore, a randomized cyanoacrylate (BCA), an intermediate-length CA, is clinical trial involving 94 patients who had facial not toxic when applied topically.
    [Show full text]
  • Effectiveness of Cyanoacrylate Glue in The
    EFFECTIVENESS OF CYANOACRYLATE GLUE IN THE MANAGEMENT 0F LOW ANAL FISTULA Dissertation submitted to The Tamil Nadu M.G.R Medical University Chennai- 600032 In partial fulfillment of the Regulations of the award of degree of M.S. General Surgery (Branch – I) Department of General Surgery Coimbatore Medical College Hospital Coimbatore – 641014 April - 2014 1 CERTIFICATE Certified that this is the bonafide dissertation done by DR.S.MURUGESAN and submitted in partial fulfillment of the requirement for the Degree of M.S.General surgery, Branch I of The TamilnaduDr.M.G.R. Medical University, Chennai Date; Unit Chief Date; Professor & Head Department of surgery Date; Dean Coimbatore Medical College Coimbatore-641014 2 DECLARATION I solemnly declare that the dissertation titled ‘’EFFECTIVENESS OF CYANOACRYLATE GLUE IN THE MANAGEMENT OF LOW ANAL FISTULA’’ Was done by me from 2012 onwards under the guidance And supervision of Prof.Dr.D.N.RENGANATHAN, M.S. This dissertation is submitted to theTamilnaduDr.MGR Medical University towards the partial fulfillment of the requirement for the award of M.S Degree in General Surgery (Branch I). Place : Dr.S.MURUGESAN Date : 3 4 5 6 ACKNOWLEDGEMENT I owe my reverential gratitude and humble thanks to Lord God Almighty for all his mercy, for being with me and showering abundant blessing upon me throughout the course of study I am obliged to record my immense gratitude to DR. VIMALA The Dean, Coimbatore Medical College hospital for providing all the facilities to conduct the studies. I express my deep sense of gratitude and heart felt thanks to Professor DR.
    [Show full text]
  • The Efficacy of N-Butyl-2 Cyanoacrylate (Histoacryl) For
    perim Ex en l & ta a l ic O p in l h t C h f Journal of Clinical & Experimental a o l m l a o n l r o Tan et al., J Clin Exp Ophthalmol 2015, 6:2 g u y o J Ophthalmology 10.4172/2155-9570.1000420 ISSN: 2155-9570 DOI: Research Article Open Access The Efficacy of N-Butyl-2 Cyanoacrylate (Histoacryl) for Sealing Corneal Perforation: A Clinical Case Series and Review of the Literature Jackie Tan1, Yi-Chiao Li1,2, John Foster3 and Stephanie L Watson1 1Save Sight Institute, University of Sydney, Australia 2Geelong Hospital, Victoria, Australia 3Bio/Polymer Research Group, School of Biotechnology and Biomolecular Sciences, the University of New South Wales Corresponding author: Jackie Tan, Save Sight Institute, Sydney Eye Hospital, Australia, Tel: +61 431735162; Email: [email protected] Received date: Feb 25, 2015, Accepted date: Apr 15, 2015, Published date: Apr 20, 2015 Copyright: © 2015 Tan J, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Abstract Purpose: To investigate the efficacy of corneal gluing procedures for corneal perforations of mixed aetiologies in a tertiary eye hospital in Sydney, Australia. Design: Retrospective case series. Methods: Episodes of corneal gluing procedures were identified from the Sydney Eye Hospital surgical database over 42 months from January 2010. All gluing procedures in this study were conducted in the operating theatre. Categorical variables were compared using Pearson’s chi-square test.
    [Show full text]